#CTAD26: Lilly’s dopamine drug mevidalen fails Phase 2 study in Alzheimer’s
BOSTON — A little-known therapy Eli Lilly has quietly been testing in people with mild and moderate Alzheimer’s disease has failed in its Phase 2 study. The experimental drug, called mevidalen, was dropped ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.